Expression system of fusion protein from human serum albumin and interleukin-1 receptor antagonist

A technology of human serum albumin and receptor antagonist, applied in the field of protein expression system, can solve the problem of low expression level of fusion protein, and achieve the effects of low immunogenicity, improved expression level and favorable clinical application.

Active Publication Date: 2012-11-07
ZHEJIANG UNIV
View PDF1 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] The present invention provides an expression system for the fusion protein of human serum albumin and interleukin-

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Expression system of fusion protein from human serum albumin and interleukin-1 receptor antagonist
  • Expression system of fusion protein from human serum albumin and interleukin-1 receptor antagonist
  • Expression system of fusion protein from human serum albumin and interleukin-1 receptor antagonist

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] Example 1 Construction of plasmid pPIC9-IGH, and obtaining DNA sequence capable of expressing IGH protein

[0036] Using the plasmids PGEM-T-HSA and PGEM-T-IL1ra disclosed in Patent Application No. 200810060568.7 as templates, primers IL1ra up (SEQ ID NO. 16) and IL1ra dn (SEQ ID NO. 17) were designed according to the sequences of IL1ra gene and HSA gene. ), HSAup (SEQ ID NO. 18) and HSA dn (SEQ ID NO. 19) for PCR amplification. Since the base sequence of the BamH I restriction site exactly encodes -GS-, the codon encoding the connecting peptide -GGGGS- is designed at the 5'end of IL1ra dn, and the BamH I restriction site is also designed. A BamHI restriction site is also added at the up 5'end of HSA, so that the IL1ra gene and HSA gene can be fused by BamHI restriction and ligation. The IL1ra gene amplification product was digested with Xho I and BamH I and recovered. The HSA gene amplification product was digested with BamH I and EcoR I and recovered. The empty pPIC9 pl...

Embodiment 2

[0038] Example 2 Construction of recombinant plasmid pPICZαB-IGH

[0039] The empty pPICZαB vector was digested with Xho I and Not I, and the vector fragments were recovered by electrophoresis. The digested pPICZαB vector and the IGH expression sequence obtained in Example 1 were mixed in an appropriate ratio, and ligated with T4 ligase in a 16°C water bath for 12 hours to form pPICZαB-IGH (see the construction principle figure 1 ). After pPICZαB-IGH was transformed into DH5α, it was plated on an LB agar plate containing 25μg / mL Zeocin and incubated at 37°C overnight. Select several clones on the plate to inoculate 5mL LB liquid medium containing 25μg / mL Zeocin, and cultivate overnight at 37℃. The obtained positive clones were sent to Shanghai Shenggong for sequencing for verification.

Embodiment 3

[0040] Example 3 Transformation of GS115 by recombinant plasmid pPICZαB-IGH

[0041] The verified pPICZαB-IGH plasmid obtained in Example 2 was linearized with Pme I and transformed into Pichia pastoris GS115 by electrotransformation. The transformed cells were incubated in YPD liquid medium at 30°C for 2 hours, and then coated To YPDS agar plates containing 100, 700 or 1500 μg / mL Zeocin (1% yeast extract, 2% peptone, 2% glucose, 1M sorbitol, 2% agarose, 1M sorbitol). After culturing at 30°C for 3 days, about 200, 4, and 0 single colonies were grown on YPDS agar plates with 100, 700 or 1500 μg / mL Zeocin. Pick 5 (named L1~5) and 4 (named H1~4) single colonies on YPDS agar plates with 100 and 700 μg / mL Zeocin, respectively.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an expression system of fusion protein from human serum albumin and interleukin-1 receptor antagonist. The expression system comprises a host cell and an expression vector transferred into the same. The expression vector comprises a first expression vector with an inserted fusion protein gene and a second expression vector with an inserted protein disulfide isomerase gene.The fusion protein gene comprises the human serum albumin and the interleukin-1 receptor antagonist. The host cell is Pichia pastoris GS115. The co-expression host of PDI (protein disulfide isomerase) and IGH (immunoglobulin heavy) is established, and expression index of the IGH is evidently increased. The PDI is expressed intracellularly, the IGH secretory expression is subjected to extracellular secretory expression, and accordingly no newly generated other proteins occur when concentration of the IGH in collected medium supernate increases.

Description

Technical field [0001] The invention relates to a protein expression system, in particular to an expression system of a fusion protein of human serum albumin and an interleukin 1 receptor antagonist. Background technique [0002] The Pichia pastoris expression system is a relatively successful eukaryotic expression system for foreign proteins in recent years. Compared with the E. coli expression system, it can better express complex proteins, and can complete Such post-translational modifications as disulfide bond formation. Compared with mammalian cells and insect cell expression systems, it has the advantages of simple operation, high expression, and easy industrialization and amplification. [0003] Interleukin 1 receptor antagonist (IL1ra) is a protein that can bind to IL1 receptor, and when it binds to IL1 receptor, it can block the biological activity of IL1. Therefore, a certain concentration of IL1ra can neutralize the biological activities of these two cytokines in physi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12N15/81C12N1/19C12R1/84
Inventor 陈枢青沈其
Owner ZHEJIANG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap